Globe Newswire

STOCKHOLM, Sweden, June 12 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has received the final permission required to test its lead candidate drug BSG005 in patients with invasive fungal infections in India.

Biosergen and its partner, Alkem Laboratories Limited, have received approval of the Clinical Trial Application (CTA) and an important import license in India. With the approval and import license in... (continue reading...)

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE / DEALING BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR   MORE   Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

JERICHO, N.Y., June 12, 2024 (GLOBE NEWSWIRE) -- Nathan's Famous, Inc. (NASDAQ: NATH) today reported results for its fiscal year and fourth quarter ended March 31, 2024.

Effective June 12, 2024, the Board of Directors declared its first quarterly cash dividend for fiscal 2025 of $0.50 per share, which is payable on July 2, 2024 to shareholders of record at the close of business on June 24, 2024.

For the fiscal year ended March 31, 2024:

• Revenues were $138,610,000... (continue reading...)

- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) -

- AFM28 shows single agent efficacy with 2 CR/CRi and 3 stable disease (SD) in 6 patients treated at dose level of 300 mg weekly -

• Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells: Recruitment in cohorts 1 and 2 completed. In the first 7 treatment refractory Hodgkin Lymphoma (HL) patients,... (continue reading...)